Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial

Abstract

AbstractAimTo examine the effects of the thiazolidinedione (TZD) pioglitazone on reducing ketone bodies in non‐obese patients with T2DM treated with the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin.MethodsCrossover trials with two periods, each treatment period lasting 4 weeks, with a 4‐week washout period, were conducted. Participants were randomly assigned in a 1:1 ratio to receive pioglitazone combined with canagliflozin (PIOG + CANA group) versus canagliflozin monotherapy (CANA group). The primary outcome was change (Δ) in β‐hydroxybutyric acid (β‐HBA) before and after the CANA or PIOG + CANA treatments. The secondary outcomes were Δchanges in serum acetoacetate and acetone, the rate of conversion into urinary ketones, and Δchanges in factors related to SGLT2 inhibitor‐induced ketone body production including non‐esterified fatty acids (NEFAs), glucagon, glucagon to insulin ratio, and noradrenaline (NA). Analyses were performed in accordance with the intention‐to‐treat principle.ResultsTwenty‐five patients with a mean age of 49 ± 7.97 years and a body mass index of 25.35 ± 2.22 kg/m2 were included. One patient discontinued the study during the washout period. Analyses revealed a significant increase in the levels of serum ketone bodies and an elevation in the rate of conversion into urinary ketones after both interventions. However, differernces in levels of ketone bodies (except for acetoacetate) in the PIOG + CANA group were significantly smaller than in the CANA group (219.84 ± 80.21 μmol/L vs. 317.69 ± 83.07 μmol/L, p < 0.001 in β‐HBA; 8.98 ± 4.17 μmol/L vs. 12.29 ± 5.27 μmol/L, p = 0.018 in acetone). NEFA, glucagon, glucagon to insulin ratio, and NA were also significantly increased after both CANA and PIOG + CANA treatments; while only NEFAs demonstrated a significant difference between the two groups. Correlation analyses revealed a significant association between the difference in Δchanges in serum NEFA levels with the differences in Δchanges in ketones of β‐HBA and acetoacetate.ConclusionSupplementation of pioglitazone could alleviate canagliflozin‐induced ketone bodies. This benefit may be closely associated with decreased substrate NEFAs rather than other factors including glucagon, fasting insulin and NA.